Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15957833 | 0.95 | GRM5 (0.40) | GRM5CYP2A6PRMT5WDR77 | |
| SCHEMBL31014462 | 0.89 | GRM5 (0.51) | GRM5CYP2A6PRMT5WDR77 | |
| SCHEMBL31014678 | 0.87 | GRM5 (0.34) | GRM5CYP2A6PRMT5WDR77BACE1 | |
| SCHEMBL14903886 | 0.85 | GRM5 (0.51) | GRM5CYP2A6PRMT5WDR77EGLN1 | |
| SCHEMBL15996479 | 0.85 | APP (0.32) | GRM5CYP2A6PRMT5WDR77BACE1 | |
| SCHEMBL15999715 | 0.85 | GRM5 (0.51) | GRM5CYP2A6 | |
| SCHEMBL23181491 | 0.84 | PRMT5 (0.33) | GRM5CYP2A6PRMT5WDR77CYP1A1 | |
| SCHEMBL931245 | 0.84 | GRM5 (0.51) | GRM5CYP2A6PRMT5WDR77PARP1 | |
| SCHEMBL12938287 | 0.84 | GRM5 (0.39) | GRM5CYP2A6PRMT5WDR77BACE1 | |
| SCHEMBL12827266 | 0.84 | PRMT5 (0.33) | GRM5CYP2A6PRMT5WDR77CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368317-B1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-12-27 | — | — | EP | disclosed |
| US-7060716-B2 | Compound containing two triple bonds | ALTANA PHARMA AG (DE) | 2006-06-13 | — | — | US | disclosed |
| US-20040067943-A1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2004-04-08 | — | — | US | disclosed |
| EP-1368317-A1 | TRYPTASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002066430-A1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067943-A1 | Tryptase inhibitors | TPSB2, TPSAB1, TPSG1 | GRM5 2829/4885CYP2A6 992/4885PRMT5 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.